Protein biosensors show promise for SARS-CoV-2 testing

By Leah Sherwood, contributing writer

February 1, 2021 -- Scientists have developed biosensors to detect SARS-CoV-2 proteins and antibodies in simulated nasal fluids and human sera, according to a study published in Nature on January 27. The approach promises to be less costly and time-consuming than current COVID-19 testing methods.

Biosensors are devices used to detect the presence or concentration of specific biomolecules or biological structures. In this case, the researchers designed protein-based biosensors that recognize specific molecules on the surface of a particular virus and bind to them, then emit light through a biochemical reaction.

The scientists applied this approach to design biosensors of antibodies against SARS-CoV-2 protein epitopes and of the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein.

The result was a biosensor that glows when mixed with COVID-19 antibodies.

The researchers were able to demonstrate that their SARS-CoV-2 biosensor does not react to other antibodies that might also be in the blood, including those that target other viruses, which is an important consideration for avoiding false-positive test results.

An illustration of a new biosensor binding to a targeted molecule and emitting light
An illustration of a new biosensor binding to a targeted molecule and emitting light. Image courtesy of Ian Haydon/Institute for Protein Design at the University of Washington.

The researchers hope that their approach will lead to faster testing in clinical settings. Currently, SARS-CoV-2 infections are routinely diagnosed using reverse transcription polymerase chain reaction (RT-PCR). However, RT-PCR is a slow process that relies on specialized skills and equipment in the laboratory. Furthermore, the COVID-19 pandemic has created shortages in lab supplies and other supply chain issues that slow down patients' test results even further.

In contrast, luminescence-based protein biosensors offer an attractive approach to testing, particularly at the point of care, because they promise a nearly instantaneous readout. Furthermore, the quantification of luminescence can be carried out with inexpensive equipment such as a cell phone camera.

"We have shown in the lab that these new sensors can readily detect virus proteins or antibodies in simulated nasal fluid or donated serum," said David Baker, PhD, director of the Institute for Protein Design at the University of Washington, in a statement. "Our next goal is to ensure they can be used reliably in a diagnostic setting. This work illustrates the power of de novo protein design to create molecular devices from scratch with new and useful functions."

In addition to their biosensor model for detection of SARS-CoV-2, the scientists also demonstrated that similar models can be designed to detect proteins associated with cancer, namely human epidermal growth factor receptor 2 (HER2, breast cancer) and B-cell lymphoma 2 (BCL-2, lymphoma), and to detect hepatitis B antibodies.

CAP comments on Biden's COVID-19 plans
The College of American Pathologists (CAP) released a letter on January 27 detailing how the Biden administration can better combat the COVID-19 pandemic...
Creator of Rutgers COVID-19 saliva test dies
The Rutgers University researcher who created the first approved COVID-19 saliva test, Andrew Brooks, PhD, died unexpectedly at age 51 on January 23.
COVID-19 testing boosts molecular point-of-care market
In 2021, Kalorama Information estimates the market for molecular point-of-care diagnostics will be worth $900 million. Not surprisingly, COVID-19...
Hexapod personal protective booths cut testing costs for COVID-19
As the COVID-19 pandemic continues to evolve, hospitals and labs have had to get creative, overcome hurdles, and adapt their practices to perform safer...
Quest wins CDC contract to sequence COVID-19 gene variants
Quest Diagnostics has received a contract from the U.S. Centers for Disease Control and Prevention (CDC) to provide genomic sequencing for a project aimed...

Copyright © 2021

Last Updated bc 2/2/2021 7:41:27 AM